The new drug Camzyos for obstructive hypersatic myocardial infarction is entering the general hospital prescription. According to the related industry, Camzyos of BMS Pharmaceutical Korea has passed the Drug Committee (DC) of medical institutions such as SMC and Sinchon Severance Hospital.
Camzyos is the first and only treatment that selectively inhibits the excessive cross-bining of cardiac myosine and acttin, the cause of obstructive hypertrophic cardiomyopathy (oHCM). The drug has the mechanism of separating myosine from actin and relaxing the excessively contracted heart muscle, improving occlusion with an inflated left ventricle structure and left ventricle leaks. The clinical trial based on the Camzyos